SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 3, 2007
EPIX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
|
|
|
000-21863
|
|
04-3030815 |
|
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
|
|
|
4 Maguire Road, Lexington, Massachusetts
|
|
02421 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (781) 761-7600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Item 3.01 |
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
EPIX Pharmaceuticals, Inc. (the Company) announced that it will request a hearing before the
NASDAQ Listing Qualifications Panel (the Panel) in response to the receipt of a NASDAQ Staff
Determination Letter on April 3, 2007 indicating that the Company is not in compliance with
Marketplace Rule 4310(c)(14), which requires timely filing of periodic reports with NASDAQ for
continued listing. As anticipated, the letter was issued in accordance with NASDAQs procedures as
a result of the delayed filing of the Companys Annual Report on Form 10-K for the fiscal year
ended December 31, 2006. Pending a decision by the Panel, the Companys shares will continue to be
listed on the NASDAQ Global Market. There can be no assurance that the Panel will grant the
Companys request for continued listing.
|
|
|
Item 7.01 |
|
Regulation FD Disclosure. |
On April 3, 2007, EPIX Pharmaceuticals, Inc. issued a press release, a copy of which is being
furnished as Exhibit 99.1 to this current report on Form 8-K.
The
information in this item of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is
intended to be furnished and shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such
filing.
|
|
|
Item 9.01 |
|
Financial Statements and Exhibits. |
|
99.1 |
|
Press Release issued by the registrant on April 3, 2007, furnished herewith. |